^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

LBA56 - MEDI5752 or pembrolizumab (P) plus carboplatin/pemetrexed (CP) in treatment-naïve (1L) non-small cell lung cancer (NSCLC): A phase Ib/II trial

Published date:
09/05/2022
Excerpt:
DOR, PFS and OS were higher in M1500+C vs P+C in ITT and PD-L1<1%...In M750+C (n=50; 70% PD-L1<1%), at median follow-up of ∼3.9 months, emerging efficacy shows 44% ORR in ITT and 48% in PD-L1<1%...M1500+C improved DOR, PFS and OS compared to P+C in a randomized signal finding trial in 1L Nsq NSCLC. Emerging data with M750+C shows similarly encouraging efficacy, especially in PD-L1<1% subgroup, with improved tolerability.
Secondary therapy:
carboplatin
Trial ID: